Organization
Georges François Leclerc Comprehensive Cancer Care Centre
6 abstracts
Abstract
Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.Org: Nantes Université, CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, University Hospitals Leuven, Leuven Cancer Institute, and BGOG,
Abstract
Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).Org: INSERM, EFS UFC, UMR1098, RIGHT, University of Franche-Comté, Besançon, France, Gustave Roussy Cancer Center, Bordeaux Population Health, Unicancer, Jean Godinot Cancer Institute,
Abstract
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.Org: PACAN platform, Unité d'Oncogériatrie, Department of Geriatrics, Institut Paoli-Calmettes, Marseille, France, Institut Curie, Saint Cloud, France,
Abstract
Optimization of surgical management of the axilla since MonarchE trial.Org: Georges François Leclerc Comprehensive Cancer Care Centre, Centre Georges François Leclerc, Centre Georges Francois Leclerc,
Abstract
PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.Org: Institut Bergonie, Institut Bergonié, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Institut Paoli Calmettes, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,